देश: पुर्तगाल
भाषा: अंग्रेज़ी
स्रोत: HMA (Heads of Medicines Agencies)
pimobendan 10 mg
BOEHRINGER INGELHEIM ESPAÑA
QC01CE90
Capsule, hard
pimobendane
Dogs Non Food
2013-04-24
1 SUMMARY OF PRODUCT CHARACTERISTICS 2 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vetmedin 10 mg capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains: Active substance Pimobendan 10 mg Excipients Titanium dioxide (E171) 1.920 mg Red iron oxide (E172) 0.154 mg Black iron oxide (E172) 0.031 mg Erythrosin (E127) 0.077 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Capsule, hard. Oblong hard gelatine capsule with a pink opaque cap and a white opaque body. 4. CLINICAL PARTICULARS 4.1. TARGET SPECIES Dogs 4.2. INDICATIONS FOR USE , SPECIFYING THE TARGET SPECIES For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation). 4.3. CONTRAINDICATIONS Do not use in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis). Do not use in case of hypersensitivity to the active substance or to any of the excipients. 4.4. SPECIAL WARNINGS In diabetic animals, glucose levels have to be strictly controlled. Absorption of this product is modified when administered with food. Therefore, the optimum efficacy is granted when the stomach is empty. The product should be given one hour before feeding. 3 4.5. SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS F पूरा दस्तावेज़ पढ़ें
1 SUMMARY OF PRODUCT CHARACTERISTICS 2 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vetmedin 10 mg capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains: Active substance Pimobendan 10 mg Excipients Titanium dioxide (E171) 1.920 mg Red iron oxide (E172) 0.154 mg Black iron oxide (E172) 0.031 mg Erythrosin (E127) 0.077 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Capsule, hard. Oblong hard gelatine capsule with a pink opaque cap and a white opaque body. 4. CLINICAL PARTICULARS 4.1. TARGET SPECIES Dogs 4.2. INDICATIONS FOR USE , SPECIFYING THE TARGET SPECIES For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation). 4.3. CONTRAINDICATIONS Do not use in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis). Do not use in case of hypersensitivity to the active substance or to any of the excipients. 4.4. SPECIAL WARNINGS In diabetic animals, glucose levels have to be strictly controlled. Absorption of this product is modified when administered with food. Therefore, the optimum efficacy is granted when the stomach is empty. The product should be given one hour before feeding. 3 4.5. SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS F पूरा दस्तावेज़ पढ़ें